William Bernal1, Nicholas Murphy2, Sarah Brown3, Tony Whitehouse2, Peter Nissen Bjerring4, John Hauerberg5, Hans J Frederiksen6, Georg Auzinger3, Julia Wendon3, Fin Stolze Larsen4. 1. Liver Intensive Care Unit, Institute of Liver Studies, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. Electronic address: william.bernal@kcl.ac.uk. 2. Department of Anaesthesia and Critical Care, University Hospital Birmingham, Birmingham B15 2GW, United Kingdom. 3. Liver Intensive Care Unit, Institute of Liver Studies, Kings College Hospital, Denmark Hill, London SE5 9RS, United Kingdom. 4. Department of Hepatology, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark. 5. Department of Neurosurgery, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark. 6. Department of Anaesthesia, Rigshospitalet, University Hospital Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Abstract
BACKGROUND & AIMS: Animal models and human case series of acute liver failure (ALF) suggest moderate hypothermia (MH) to have protective effects against cerebral oedema (CO) development and intracranial hypertension (ICH). However, the optimum temperature for patient management is unknown. In a prospective randomized controlled trial we investigated if maintenance of MH prevented development of ICH in ALF patients at high risk of the complication. METHODS:Patients with ALF, high-grade encephalopathy and intracranial pressure (ICP) monitoring in specialist intensive care units were randomized by sealed envelope to targeted temperature management (TTM) groups of 34°C (MH) or 36°C (control) for a period of 72h. Investigators were not blinded to group assignment. The primary outcome was a sustained elevation in ICP >25mmHg, with secondary outcomes the occurrence of predefined serious adverse effects, magnitude of ICP elevations and cerebral and all-cause hospital mortality (with or without transplantation). RESULTS:Forty-six patients were randomized, of whom forty-three were studied. There was no significant difference between the TTM groups in the primary outcome during the study period (35% vs. 27%, p=0.56), for the MH (n=17) or control (n=26) groups respectively, relative risk 1.31 (95% CI 0.53-3.2). Groups had similar incidence of adverse events and overall mortality (41% vs. 46%, p=0.75). CONCLUSIONS: In patients with ALF at high risk of ICH, MH at 33-34°C did not confer a benefit above management at 36°C in prevention of ICH or in overall survival. This study did not confirm advantage of its prophylactic use. (ISRCTN registration number 74268282; no funding.) LAY SUMMARY: Studies in animals with acute liver failure (ALF) have suggested that cooling (hypothermia) could prevent or limit the development of brain swelling, a dangerous complication of the condition. There is limited data on its effects in humans. In a randomized controlled trial in severely ill patients with ALF we compared the effects of different temperatures and found no benefit on improving survival or preventing brain swelling by controlling temperature at 33-34°C against 36°C.
RCT Entities:
BACKGROUND & AIMS: Animal models and human case series of acute liver failure (ALF) suggest moderate hypothermia (MH) to have protective effects against cerebral oedema (CO) development and intracranial hypertension (ICH). However, the optimum temperature for patient management is unknown. In a prospective randomized controlled trial we investigated if maintenance of MH prevented development of ICH in ALFpatients at high risk of the complication. METHODS:Patients with ALF, high-grade encephalopathy and intracranial pressure (ICP) monitoring in specialist intensive care units were randomized by sealed envelope to targeted temperature management (TTM) groups of 34°C (MH) or 36°C (control) for a period of 72h. Investigators were not blinded to group assignment. The primary outcome was a sustained elevation in ICP >25mmHg, with secondary outcomes the occurrence of predefined serious adverse effects, magnitude of ICP elevations and cerebral and all-cause hospital mortality (with or without transplantation). RESULTS: Forty-six patients were randomized, of whom forty-three were studied. There was no significant difference between the TTM groups in the primary outcome during the study period (35% vs. 27%, p=0.56), for the MH (n=17) or control (n=26) groups respectively, relative risk 1.31 (95% CI 0.53-3.2). Groups had similar incidence of adverse events and overall mortality (41% vs. 46%, p=0.75). CONCLUSIONS: In patients with ALF at high risk of ICH, MH at 33-34°C did not confer a benefit above management at 36°C in prevention of ICH or in overall survival. This study did not confirm advantage of its prophylactic use. (ISRCTN registration number 74268282; no funding.) LAY SUMMARY: Studies in animals with acute liver failure (ALF) have suggested that cooling (hypothermia) could prevent or limit the development of brain swelling, a dangerous complication of the condition. There is limited data on its effects in humans. In a randomized controlled trial in severely ill patients with ALF we compared the effects of different temperatures and found no benefit on improving survival or preventing brain swelling by controlling temperature at 33-34°C against 36°C.
Authors: Filipe S Cardoso; Mark J Mcphail; Constantine J Karvellas; Valentin Fuhrmann; Nuno Germano; Georg Auzinger Journal: GE Port J Gastroenterol Date: 2021-05-25
Authors: Vitaly I Pozdeev; Elisabeth Lang; Boris Görg; Hans J Bidmon; Prashant V Shinde; Gerald Kircheis; Diran Herebian; Klaus Pfeffer; Florian Lang; Dieter Häussinger; Karl S Lang; Philipp A Lang Journal: Sci Rep Date: 2017-08-11 Impact factor: 4.379
Authors: Kevin Roedl; Christian Wallmüller; Andreas Drolz; Thomas Horvatits; Karoline Rutter; Alexander Spiel; Julia Ortbauer; Peter Stratil; Pia Hubner; Christoph Weiser; Jasmin Katrin Motaabbed; Dominik Jarczak; Harald Herkner; Fritz Sterz; Valentin Fuhrmann Journal: Ann Intensive Care Date: 2017-10-06 Impact factor: 6.925
Authors: Andrea M Robinson; C J Karvellas; Joanna C Dionne; Robin Featherstone; Meghan Sebastianski; Ben Vandermeer; Oleksa G Rewa Journal: Syst Rev Date: 2020-06-16